Contineum launches global Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis patients

Contineum Therapeutics has launched a global Phase 2 trial for PIPE-791, an oral LPAR1 antagonist, in patients with idiopathic pulmonary fibrosis. The update accompanies a newly published discovery paper from June 29, 2026, which details preclinical findings of sustained receptor coverage with once-daily dosing. These results support the company's plans to investigate PIPE-791 for fibrotic diseases and pain indications.

Contineum Therapeutics highlighted PIPE-791, an oral LPAR1 antagonist now in a global Phase 2 trial in idiopathic pulmonary fibrosis. * No clinical results were presented; the update centered on a newly published discovery paper dated June 29, 2026. * Preclinical findings described sustained receptor coverage with once-daily dosing, supporting plans to pursue fibrotic disease and pain indications. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606301605BIZWIRE_USPR_____20260630_BW868477) on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Contineum Therapeutics highlighted PIPE-791, an oral LPAR1 antagonist now in a global Phase 2 trial in idiopathic pulmonary fibrosis. * No clinical results were presented; the update centered on a newly published discovery paper dated June 29, 2026. * Preclinical findings described sustained receptor coverage with once-daily dosing, supporting plans to pursue fibrotic disease and pain indications. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606301605BIZWIRE_USPR_____20260630_BW868477) on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)